Contraline News
All posts

April 13, 2017

Contraline Secures $2.25 millionin Seed Financing

CHARLOTTESVILLE, Virginia Contraline, a biotechnology company developing a novel male contraceptive, announced it has raised 2.25 million in Seed funding. The round was led by San Francisco-based venture capital firm, Founders Fund, with investments also coming from Center for Innovative Technology, Abstract Ventures, Afton Scientific, and angel investors including Jaffray Woodriff and Jason Calacanis.Co-Founder and CEO Kevin Eisenfrats stated, Were thrilled to bring in a group of new and existing investors who believe in our vision of commercializing the first long-lasting, reversible male contraceptive. Many of these investors have followed our work and have seen how much progress weve made in a relatively short period of time.Contraline plans on using these funds to continue the research and development of its male contraceptive product, Echo-V, a polymer gel that is implanted into the vas deferens to block sperm flow. The Company also plans to initiate pre-clinical trials for Echo-V later this year. Overall, our goal is to deliver a new male contraceptive product to market by 2021 with the goal of replacing the vasectomy market by 2026, says Eisenfrats.In addition to being reversible, Contralines procedure Vasintomy is intended to be non-surgical. Rather than making an incision and exteriorizing the vas deferens like in vasectomy, urologists use an ultrasound to guide the injection through the skin. Therefore, no incisions, scalpels, or sutures are required. The procedure is anticipated to be 3-4 times faster and have less complications than vasectomy.Contraline recently moved into its new headquarters, ContraLab, a 2,200 sq. ft. lab and office space in Charlottesville, VA. The company plans on using this space for all polymer synthesis and characterization work, with animal studies taking place at various universities and contract research organizations that Contraline partners with.The Company has raised a total of 3.1 million to date including a previous round of funding from angel investors, grants, and multiple university and national awards.More information about the fundraise can be found on TechCrunchhttpstechcrunch.com20170405meet-the-company-thats-looking-to-make-non-surgical-male-birth-control-a-reality.

December 08, 2016

Contraline Accelerates Growth with Expansion into New Laboratory

CHARLOTTESVILLE, Virginia Earlier this fall, Contraline moved its operations from the University of Virginia School of Medicine into its new headquarters in Charlottesville, called ContraLab. ContraLab is a 2200 sq. ft. office and laboratory space located at 1216 Harris Street. The laboratory space will be used primarily for research and product development including synthesizing and characterizing its vas-occlusive male contraceptive, Echo-V. Contraline will continue to maintain a close relationship with the University of Virginia, where small animal trials and clinical research are taking place. At a Grand Opening celebration later this month, Contraline will officially name the lab The Herr Lab after the companys co-founder, Dr. John Herr, who passed away earlier this year. Kevin Eisenfrats, Contralines co-founder and CEO, states, Moving into our own headquarters signifies the next stage of opportunity and growth for Contraline. ContraLab provides the ability for us to add to our scientific team, build on our company culture, and focus on product development in an environment defined by our needs. In addition to the new space, joining Contraline as chief operating officer is Nikki Hastings. Dr. Hastings is an operations executive, engineer, and entrepreneur. Previously, Nikki served as vice president of operations at HemoShear Therapeutics where she was on the founding team developing the core technology. She is experienced in technology transfer and commercialization, organizational development and growth, laboratory build-out, development of internal processes and recruiting strategies. Nikki received her Ph.D. in biomedical engineering from the University of Virginia. Eisenfrats concluded, Given the incredibly motivated and interdisciplinary team, Contraline is well on its path to successfully commercializing the first long-lasting, reversible male contraceptive.

June 13, 2016

Contraline Awarded $50,000 from Center for Innovative Technology

CHARLOTTESVILLE, Virginia Contraline is excited to announce its selection as an awardee for the 2016 Research Commercialization Award. This distinction is supported by the Center for Innovative Technologys Commonwealth Research Commercialization Fund CRCF. The mission of this fund is to accelerate innovation and economic growth in Virginia by advancing solutions to important state, national, and international problems through technology research, development, and commercialization. Since its inception in 2012, the CRCF has awarded funding to over 180 projects from around the commonwealth on topics ranging from data analytics to life sciences. This year, CRCF awarded 3.4 million in funding to support 48 projects around the state of Virginia. Contraline was selected as one of 20 companies specifically for the Commercialization Program. Contraline plans to use the funding to perform proof-of-concept studies on echogenic polymer gels for vas-occlusive contraception and investigating novel methods for reversing them. In announcing this years awards, Virginia Governor Terry McAuliffe stated We will continue to support emerging sectors that are pushing the boundaries of exciting research and development to help build the new Virginia economy. Contraline is grateful for the states generosity and looks forward to sharing the potential breakthroughs made possible by these funds.

May 13, 2016

Contraline is acceptedinto Y Combinator Fellowship

This summer, Contraline will be a part of Y Combinators Fellowship program Y Combinator is one of the top startup accelerators in the world having funded companies like Airbnb, Dropbox, and Stripe. Recently, Y Combinator has been investing in more biotech companies given the incredible technology, economical, and social impact these companies are having. The fellowship program only in its third batch allows our company to continue working from our research lab in Charlottesville, Virginia while receiving mentorship, resources, and connections virtually. We are looking forward to seeing the growth that Contraline will have this summer as a YC-backed company

September 27, 2017

Acceptability of a Long-LastingReversible Male Contraceptive

This article, written by Contralines CEO Kevin Eisenfrats, was originally postedhttpsctiexchange.orgfinding-acceptable-long-acting-reversible-male-contraceptive to FHI360s Contraceptive Technology Innovation CTI Exchange as part of their guest-author blog series. Almost every month or so, an article is published that reads New male contraceptive is on the horizon MIT Tech Reviewhttpswww.technologyreview.coms608333the-tech-world-is-convinced-2021-is-going-to-be-the-best-year-ever has even gone so far as to say that male birth control might be one of the most interesting technologies to be released in 2021, alongside electric vehicles, virtual reality, and lab-grown chickens. Judging by the headlines, youd think that men are as excited to try a male contraceptive as they are to drive the Tesla Model 3.Are they excited We know for sure that men are NOT excited about existing methods. Condoms have a dissatisfaction rate of 57 and the number of vasectomies performed in the U.S. has stagnated at 500,000 per year. We also know that men ARE interested in controlling their fertility over the long-term. In a 2005 studyhttpsacademic.oup.comhumreparticle202549603220 of 9,000 men across nine countries, 55 of the respondents reported being willing or very willing to use a new method of male contraception. That ranged from 28.5 in Indonesia to 71.4 in Spain. The most appealing frequency for taking the contraceptive Once per year so it seems interest among men in a long-acting contraceptive option is real.The next question then is whether a hormonal method would be acceptable. In a recent clinical trialhttpsacademic.oup.comjcemarticle-lookupdoi10.1210jc.2016-2141 sponsored by the World Health Organization, men were injected with a hormonal contraceptive under development that would provide contraception for up to a year. The study regimen was not easy each man received an injection of a testosterone and progestin derivative into his gluteus every eight weeks, and was required to come back for semen analysis and physical check-ups every two weeks. The contraceptive was found to be 96 effective a very good rating, but not as effective as vasectomy, the Pill, IUDs, or implants. However, a high number of adverse effects 1,491 to be exact, including acne, increased libido, depression, and mood disorders, were noted. Due to the high number and severity of these side effects, the World Health Organization stopped the study.Despite these study conclusionshttpsctiexchange.orgmale-hormonal-contraception-informed-step-forward, it is very important to note that more than 75 of study participants reported being willing or more than willing to use this method of contraception. Only 5 of the men who participated said they would not use the method of contraception again.If a hormonal approach is not feasible in the near-term, could a non-hormonal, long-acting, reversible contraceptive for men become a game-changer At Contraline, we are developing a vas-occlusive contraceptive device that is long-lasting, non-hormonal, and reversible. The procedure involves a quick and minimally invasive procedure known as Vasintomy, whereby a gel is implanted into the vas deferens to block sperm flow from the epididymis into the ejaculate.The holy grail for a long-term male contraceptive is reversibility. Reversibility would allow the potential market to expand from just men who are family-complete to those who are sexually active. Today, vasectomy reversals take three hours, require general anesthesia, and cost up to 15,000. Not surprisingly, only 6 of men who receive a vasectomy ever get the reversal. Vas-occlusive gels are on the horizon because reversing a gel seems easier than stitching back together a ligated vas and would come with fewer side effectshttppmj.bmj.comcontent77912656.Published data on mens acceptability of vas-occlusive contraceptives are still lacking. A recently published modeling paperhttpac.els-cdn.comS00107824173043041-s2.0-S0010782417304304-main.pdftid37810c44-9898-11e7-8f8f-00000aacb362acdnat150531669979f17effae04a8c151086063c9fbaa12 assumed a conservative acceptability rate of 10 among users who would switch from existing methods as well as brand new contraceptive users. Contraline routinely receives inquiries from men asking to participate in clinical trials. There is definitely potential user interest in a vas-occlusive device.The final piece of the puzzle will be to get provider buy-inif you make it, will physicians support its use In my discussions with numerous urologists, I have found that most are cautiously excited about the potential for a vas-occlusive contraceptive. Many of them see first-hand the interest by their patients for a long-acting, reversible option. Demonstrating that the contraceptive is safe and highly effective, and that the procedure can be performed reliably will be key to getting urologist buy-in.All in all, a long-acting, reversible contraceptive for men would truly be revolutionary. It would alleviate the pressure placed currently on women, the majority users of contraceptives. Even given the conservative modeling estimate of 10 acceptability, a new male contraceptive could decrease the number of unintended pregnancies around the world on the order of hundreds of thousands, potentially millions.Who knows Maybe a vas-occlusive device will create as much buzz as the Tesla Model 3 among men seeking to control their fertility. Aside from excitement, it surely would create a new realm of shared responsibility between partners, and could become a societal game-changer. Heres to having a new, long-acting male contraceptive in the market by 2021.

April 13, 2017

Contraline Secures $2.25 millionin Seed Financing

CHARLOTTESVILLE, Virginia Contraline, a biotechnology company developing a novel male contraceptive, announced it has raised 2.25 million in Seed funding. The round was led by San Francisco-based venture capital firm, Founders Fund, with investments also coming from Center for Innovative Technology, Abstract Ventures, Afton Scientific, and angel investors including Jaffray Woodriff and Jason Calacanis.Co-Founder and CEO Kevin Eisenfrats stated, Were thrilled to bring in a group of new and existing investors who believe in our vision of commercializing the first long-lasting, reversible male contraceptive. Many of these investors have followed our work and have seen how much progress weve made in a relatively short period of time.Contraline plans on using these funds to continue the research and development of its male contraceptive product, Echo-V, a polymer gel that is implanted into the vas deferens to block sperm flow. The Company also plans to initiate pre-clinical trials for Echo-V later this year. Overall, our goal is to deliver a new male contraceptive product to market by 2021 with the goal of replacing the vasectomy market by 2026, says Eisenfrats.In addition to being reversible, Contralines procedure Vasintomy is intended to be non-surgical. Rather than making an incision and exteriorizing the vas deferens like in vasectomy, urologists use an ultrasound to guide the injection through the skin. Therefore, no incisions, scalpels, or sutures are required. The procedure is anticipated to be 3-4 times faster and have less complications than vasectomy.Contraline recently moved into its new headquarters, ContraLab, a 2,200 sq. ft. lab and office space in Charlottesville, VA. The company plans on using this space for all polymer synthesis and characterization work, with animal studies taking place at various universities and contract research organizations that Contraline partners with.The Company has raised a total of 3.1 million to date including a previous round of funding from angel investors, grants, and multiple university and national awards.More information about the fundraise can be found on TechCrunchhttpstechcrunch.com20170405meet-the-company-thats-looking-to-make-non-surgical-male-birth-control-a-reality.

December 08, 2016

Contraline Accelerates Growth with Expansion into New Laboratory

CHARLOTTESVILLE, Virginia Earlier this fall, Contraline moved its operations from the University of Virginia School of Medicine into its new headquarters in Charlottesville, called ContraLab. ContraLab is a 2200 sq. ft. office and laboratory space located at 1216 Harris Street. The laboratory space will be used primarily for research and product development including synthesizing and characterizing its vas-occlusive male contraceptive, Echo-V. Contraline will continue to maintain a close relationship with the University of Virginia, where small animal trials and clinical research are taking place. At a Grand Opening celebration later this month, Contraline will officially name the lab The Herr Lab after the companys co-founder, Dr. John Herr, who passed away earlier this year. Kevin Eisenfrats, Contralines co-founder and CEO, states, Moving into our own headquarters signifies the next stage of opportunity and growth for Contraline. ContraLab provides the ability for us to add to our scientific team, build on our company culture, and focus on product development in an environment defined by our needs. In addition to the new space, joining Contraline as chief operating officer is Nikki Hastings. Dr. Hastings is an operations executive, engineer, and entrepreneur. Previously, Nikki served as vice president of operations at HemoShear Therapeutics where she was on the founding team developing the core technology. She is experienced in technology transfer and commercialization, organizational development and growth, laboratory build-out, development of internal processes and recruiting strategies. Nikki received her Ph.D. in biomedical engineering from the University of Virginia. Eisenfrats concluded, Given the incredibly motivated and interdisciplinary team, Contraline is well on its path to successfully commercializing the first long-lasting, reversible male contraceptive.

June 13, 2016

Contraline Awarded $50,000 from Center for Innovative Technology

CHARLOTTESVILLE, Virginia Contraline is excited to announce its selection as an awardee for the 2016 Research Commercialization Award. This distinction is supported by the Center for Innovative Technologys Commonwealth Research Commercialization Fund CRCF. The mission of this fund is to accelerate innovation and economic growth in Virginia by advancing solutions to important state, national, and international problems through technology research, development, and commercialization. Since its inception in 2012, the CRCF has awarded funding to over 180 projects from around the commonwealth on topics ranging from data analytics to life sciences. This year, CRCF awarded 3.4 million in funding to support 48 projects around the state of Virginia. Contraline was selected as one of 20 companies specifically for the Commercialization Program. Contraline plans to use the funding to perform proof-of-concept studies on echogenic polymer gels for vas-occlusive contraception and investigating novel methods for reversing them. In announcing this years awards, Virginia Governor Terry McAuliffe stated We will continue to support emerging sectors that are pushing the boundaries of exciting research and development to help build the new Virginia economy. Contraline is grateful for the states generosity and looks forward to sharing the potential breakthroughs made possible by these funds.

May 13, 2016

Contraline is acceptedinto Y Combinator Fellowship

This summer, Contraline will be a part of Y Combinators Fellowship program Y Combinator is one of the top startup accelerators in the world having funded companies like Airbnb, Dropbox, and Stripe. Recently, Y Combinator has been investing in more biotech companies given the incredible technology, economical, and social impact these companies are having. The fellowship program only in its third batch allows our company to continue working from our research lab in Charlottesville, Virginia while receiving mentorship, resources, and connections virtually. We are looking forward to seeing the growth that Contraline will have this summer as a YC-backed company

1216 Harris Street, Charlottesville, VA 22903
© 2017 Contraline, Inc. All Rights Reserved.